## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER: 20-816** 

**MICROBIOLOGY REVIEW(S)** 

## **REVIEW FOR HFD-550**

OFFICE OF NEW DRUG CHEMISTRY
MICROBIOLOGY STAFF HFD-805
Microbiologist's Review #1 of NDA 20-816
June 3, 1997

A. 1. APPLICATION NUMBER:

20-816

APPLICANT:

Alcon Laboratories, Inc.

P.O. Box 6600 Fort Worth, Texas

2. PRODUCT NAME:

AZOPT™ (brinzolamide, 1%)

- 3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: Sterile, multi-dose, brinzolamide ophthalmic suspension 1% for topical (ocular) administration. The drug product will be supplied in DROP-TAINER® LDPE bottles.
- 4. METHOD OF STERILIZATION:
- 5. PHARMALOGICAL CATAGORY and/or PRINCIPLE INDICATION: Carbonic anhydrase inhibitor indicated for treatment of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

6. DRUG PRIORITY CLASSIFICATION:

not provided

B. 1. DATE OF INITIAL SUBMISSION:

Jan. 26, 1997

2. RELATED DOCUMENTS:

3. DATE OF CONSULT:

Feb. 3, 1997

4. ASSIGNED FOR REVIEW:

Feb. 7, 1997

C. REMARKS: The entire Part 7 (Microbiology) dossier was provided on CD-ROM using Word Perfect 5.1 format. Hard copies of volumes 1.1 (summary) and 1.50 (sterilization validation) also provided.

## D. CONCLUSIONS:

The submission is recommended for approval for microbiology issues concerning sterility assurance. Specific comments are provided in "E. Review Notes".

Neal Sweeney, Ph.D.

cc: NDA 20-816 HFD-550/Division File HFD-550/Chemist/H. Patel HFD-550/CSO/L. Lobianco HFD-805/Consult File/N. Sweeney

N. Sweeney, June 3, 1997 R/D initialed by P. Cooney, June 3, 1997

15/ Por 74 Cooney 6-5-97

**APPEARS THIS WAY** ON ORIGINAL